Remdesivir treatment for patients with moderate to severe COVID-19
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.4, pp.880-887, 2022 (SCI-Expanded, Scopus, TRDizin)
- Publication Type: Article / Article
- Volume: 52 Issue: 4
- Publication Date: 2022
- Doi Number: 10.55730/1300-0144.5387
- Journal Name: TURKISH JOURNAL OF MEDICAL SCIENCES
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
- Page Numbers: pp.880-887
- Keywords: COVID-19, remdesivir, antiviral, treatment, mortality
- Open Archive Collection: AVESIS Open Access Collection
- Ondokuz Mayıs University Affiliated: Yes
Abstract
Background/aim: Remdesivir, which was first developed for the treatment of Ebola disease but failed to meet expectations, has become hope in the fight against the COVID-19 pandemic. This study aimed to evaluate risk factors for mortality and prognosis of adult moderate/severe COVID-19 patients treated with remdesivir, and safety and tolerability of 5 days of remdesivir treatment.